1. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: A practical clinical trial
- Author
-
Dante Marino Malavazzi, Carolina Valério, André Augusto Anderson Seixas, Victor Fossaluza, Roseli G. Shavitt, Juliana Belo Diniz, Dawn Morelli, Cristina Belotto-Silva, Euripedes Constantino Miguel, and Sonia Borcato
- Subjects
Adult ,Male ,Obsessive-Compulsive Disorder ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,PRÁTICA PROFISSIONAL ,Obsessive compulsive ,Fluoxetine ,Internal medicine ,mental disorders ,medicine ,Humans ,In patient ,Psychiatry ,Depression (differential diagnoses) ,Aged ,Psychiatric Status Rating Scales ,Cognitive Behavioral Therapy ,Middle Aged ,Serotonin reuptake ,medicine.disease ,Comorbidity ,Cognitive behavioral therapy ,Clinical trial ,Psychiatry and Mental health ,Clinical Psychology ,Treatment Outcome ,Psychotherapy, Group ,Female ,Psychology ,Selective Serotonin Reuptake Inhibitors ,Follow-Up Studies ,medicine.drug - Abstract
Clinical effectiveness of group cognitive-behavioral therapy (GCBT) versus fluoxetine in obsessive-compulsive disorder outpatients that could present additional psychiatric comorbidities was assessed. Patients (18–65 years; baseline Yale-Brown Obsessive-Compulsive-Scale [Y-BOCS] scores ≥ 16; potentially presenting additional psychiatric comorbidities) were sequentially allocated for treatment with GCBT (n = 70) or fluoxetine (n = 88). Mean Y-BOCS scores decreased by 23.13% in the GCBT and 21.54% in the SSRI groups (p = 0.875). Patients presented a mean of 2.7 psychiatric comorbidities, and 81.4% showed at least one additional disorder. A reduction of at least 35% in baseline Y-BOCS scores and CGI ratings of 1 (much better) or 2 (better) was achieved by 33.3% of GCBT patients and 27.7% in the SSRI group (p = 0.463). The Y-BOCS reduction was significantly lower in patients with one or more psychiatric comorbidities (21.15%, and 18.73%, respectively) than in those with pure OCD (34.62%; p = 0.034). Being male, having comorbidity of Major Depression, Social Phobia, or Dysthymia predicted a worse response to both treatments. Response rates to both treatments were similar and lower than reported in the literature, probably due to the broad inclusion criteria and the resulting sample more similar to the real world population.
- Published
- 2012
- Full Text
- View/download PDF